About GRAIL
GRAIL is a publicly listed company based in Menlo Park (United States) founded in 2016 by Mostafa Ronaghi, and was acquired by Illumina in September 2020. Circulating tumor DNA is screened for early cancer detection. GRAIL has raised $2 billion across 8 funding rounds from investors including Merck, Amazon and Tencent. The company has 1,141 employees. GRAIL was last valued at $6 billion in January 2020. Its chief executive, as recorded, is Bob Ragusa. Its website grail.com draws about 91 thousand monthly visits. GRAIL offers products and services including Galleri Test. Its focus areas include Life Sciences, Clinical Genomics, Sequencing Based and Liquid Biopsy. Its competitors include Guardant Health, Color and Delfi Diagnostics; 3 of its 3 listed competitors have raised funding.
Company details
GRAIL was founded in 2016 in Menlo Park, United States, within the biotechnology sector focused on oncology. A platform for screening circulating tumor DNA to enable cancer detection is operated by the company. The Galleri test, designed as a pan-cancer screening tool, is developed by analyzing circulating nucleic acids from blood samples. Ultra-deep sequencing techniques are employed in this proprietary platform to quantify tumor DNA levels in patients.
- Headquarters Menlo Park, United States
- Employees 1,141
- Founders Mostafa Ronaghi
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website grail.com
- Social LinkedIn X Facebook Instagram YouTube Threads
- Acquired by Illumina (Sep 2020)
- Legal Name Grail, Inc.
- Annual Revenue$147.17 M (USD)17.18as on Dec 31, 2025
- Net Profit-$408.35 M (USD)79.85as on Dec 31, 2025
- EBITDA-$377.85 M (USD)33.67as on Dec 31, 2025
- Total Equity Funding$2B (USD)
in 8 rounds
- Latest Funding Round$110M (USD), Post-IPO
Jun 2026
- InvestorsMerck
& 47 more
- Employee Count1,141
- Acquired byIllumina
(Sep 2020)
Products & Services of GRAIL
GRAIL offers a comprehensive portfolio of products and services, including Galleri Test.
Blood test for detecting multiple cancers early through DNA analysis.
Apps and channels of GRAIL
its YouTube channel GRAIL has 1.53K subscribers and 30 videos.
Videos from GRAIL
The most watched videos on GRAIL's YouTube channel, GRAIL (1.53K subscribers). Click a video to play it here.
More on GRAIL.
Funding Insights of GRAIL
GRAIL has successfully raised a total of $2B across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $110 million completed in June 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2B
- Total Rounds 8
- Last Round Post-IPO — $110M
- First Round $100M
(Jan 2016)
- Investors Count 48
All 8 funding rounds of GRAIL with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $110M | Post-IPO | – | – | |
| Oct 2025 | $325M | Post-IPO | – | – | |
| Nov 2019 | $390M | Series D | – | PSP Investments, CPP Investments | |
| May 2018 | $300M | Series C | – | Ally Bridge Group, Hillhouse | |
| Jan 2018 | $1.21B | Series B | – | – | |
| Jun 2017 | Series B | – | Dentsu Ventures | – | |
| Feb 2017 | $1.21B | Series B | – | Arch Venture Partners | |
| Jan 2016 | $100M | Series A | – | Illumina, Arch Venture Partners |
| Date | Valuation | Stage |
|---|
Full valuation and stage history of GRAIL
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $6B (Jan 2020). 48 investors in total: 46 institutional and 2 angel.
Investors in GRAIL
GRAIL has secured backing from 48 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Merck, Amazon and Tencent.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and hedge fund investments in healthcare are managed. | ally-bridge.com | Hong Kong, China | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Life-Sciences focused early and growth stage VC firm funding companies in China & the US | 6dimensionscapital.com | Pudong, China | ||
Private equity and corporate advisory services are provided. | newone.com.hk | Hong Kong, China | ||
Private equity investments and investment banking services are managed. | hprpe.com | |||
Venture capital firm investing in global startups with a focus on innovation and business support. | dentsu-v.com | |||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Investments are directed by McKesson Ventures toward early-stage healthcare startups. | ventures.mckesson.com | San Francisco, United States | ||
VC firm investing in the US | shv.com | Palo Alto, United States | ||
Investment management and philanthropic ventures linked to Bezos Expeditions. | bezosexpeditions.com |
Investor details for GRAIL
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GRAIL
367 people are tracked at GRAIL (135 in leadership, 15 in board & advisors, 217 in team); the tracked headcount is 1,141.
| Name | Role | Group |
|---|---|---|
Bob Ragusa | CEO | Leadership |
Mostafa Ronaghi | Founder | Leadership |
Alison Highlander | Svp, Head Of People | Leadership |
Jeannette Reyes | Head Of Talent Acquisition | Leadership |
Bethany Rochmann | Associate Director, Customer Relationships | Leadership |
Kristin Watson | Client Success Director, Employer Partners | Leadership |
Andy Partridge | Chief Commercial Officer | Leadership |
Donald Lang | Senior Director, Legal - Corporate Governance, M&a And Securities | Leadership |
Harpal Kumar | President, Biopharma Business & Europe | Leadership |
Michael Schumacher | Director Of Labor & Trust Partnerships | Leadership |
John M. | Associate Director - People Systems, Analytics, & Services | Leadership |
Lauren Harrison | Partner Enablement Senior Manager, Market Access | Leadership |
Erin P. | Senior Vice President, Government Affairs, Policy, And Alliance Development | Leadership |
Satnam Alag | SVP, Software Engineering & Chief Security Officer | Leadership |
Katherine Gaudio | Associate Director Of Employer Mid-market Partnerships | Leadership |
Aaron Freidin | CFO | Leadership |
Sandeep Mikkilineni | Associate Director Of Software Engineering | Leadership |
Kelsey Wolff | Director, Program Operations And People Services | Leadership |
Susan Lokker | Vice President People Services, Analytics & Systems | Leadership |
Suzanne Ho | Sr. Director, People Team | Leadership |
347 more people are available in the full profile.
Complete people profiles for GRAIL
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GRAIL
GRAIL is a publicly listed company on the NASDAQ with ticker symbol GRAL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Jun 2024
- Listed onNASDAQ: GRAL
- Listed entityGRAIL, Inc.
- Exchange sectorHealth technology
- ISINUS3847471014
- Share price$140.35 (+2.17% on the day) · 2026-10-13
- Market capitalisation$6.27B
- EPS (diluted, trailing year)$-9.75
- Volume (last session)703,107
Financials of GRAIL
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $147.2M | -$408.4M | -$377.9M |
| 2024 | $125.6M | -$2.03B | -$569.7M |
| 2023 | $93.1M | -$1.47B | -$638.2M |
| 2022 | $55.5M | -$5.40B | -$587.7M |
| 2021 | $14.6M | -$1.25B | -$1.21B |
Detailed financial statements for GRAIL
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of GRAIL
6 dated milestones of GRAIL across 10 years, from founding to its latest funding, stage changes and deals.
- Founded GRAIL is founded.
- Funding First funding round of $100.0M.
- Milestone Reaches Unicorn status.
- Exit Acquired by Illumina.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $110.0M.
Competitors of GRAIL
GRAIL has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, Color and Delfi Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| delfidiagnostics.com | 2019 | Baltimore, United States | $331.59M | Provider of DNA sequencing for cancer detection |
Detailed competitors of GRAIL
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GRAIL
The website of GRAIL (grail.com) receives about 91K visits a month and ranks #377,671 among all websites worldwide, #320 in Biotechnology and Pharmaceuticals.
- Monthly visits91K
▲ 6% vs previous month
- Unique visitors40.9K
per month
- Global rank#377,671
among all websites
- Category rank#320
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.9
- Average visit1 min 46 sec
- DevicesDesktop 56% · Mobile 44%
Websites whose visitors overlap most with GRAIL. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
galleri.com | galleri.com | 100% | #436,824 | – | |
| delfidiagnostics.com | 77% | 5.2K | #3,035,678 | View details | |
| fiercebiotech.com | 61% | 858.3K | #81,022 | View details | |
grail.learninghouse.com | grail.learninghouse.com | 56% | – | ||
| sarahcannon.com | 46% | #12,272,910 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for GRAIL
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GRAIL (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Grail
Complete news archive for GRAIL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GRAIL
GRAIL was founded in 2016.
GRAIL is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Bob Ragusa is the CEO of GRAIL, as recorded in our data.
GRAIL is a funded company, having raised a total of $2B across 8 funding rounds to date. The company's 1st funding round was a Series A of $100M, raised on Jan 2016.
GRAIL has 1,141 employees.
Annual revenue of GRAIL is $147.17M as on Dec 31, 2025.
GRAIL was founded in 2016 in Menlo Park, United States, within the biotechnology sector focused on oncology. A platform for screening circulating tumor DNA to enable cancer detection is operated by the company. The Galleri test, designed as a pan-cancer screening tool, is developed by analyzing circulating nucleic acids from blood samples. Ultra-deep sequencing techniques are employed in this proprietary platform to quantify tumor DNA levels in patients.
GRAIL's top competitors include Guardant Health, Delfi Diagnostics and Color.
GRAIL offers Galleri Test.
Yes, GRAIL is publicly traded on NASDAQ under the ticker symbol GRAL.
The valuation of GRAIL is $6B as of Jan 2020.